{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:29:43Z","timestamp":1783366183432,"version":"3.54.6"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) is a treatment option for patients with relapsed or refractory multiple myeloma that has led to unprecedented treatment outcomes. Among CAR T therapies available, ciltacabtagene autoleucel (cilta-cel) is a good candidate for outpatient administration due to its generally predictable safety profile. There are multiple advantages of outpatient administration of cilta-cel, including reduced healthcare burden, expanded access, and patient autonomy. This mixed methods qualitative study aimed to identify key factors for outpatient administration of CAR T and best practice recommendations by combining a targeted literature review with expert interviews and panels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The targeted review (Phase 1) aimed to identify factors for outpatient CAR T administration in the US and determine key topics for the exploratory interviews (Phase 2) and expert panels (Phase 3), which aimed to inform on best practices and challenges of outpatient CAR T administration (focusing on cilta-cel). Participants in clinical and administrative positions based in treatment centers that had experience with real-world outpatient administration of cilta-cel were recruited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen studies were identified in Phase 1. Key factors for outpatient administration included the development of protocols for CAR T complications, education for caregivers, outpatient specialists, hospital staff, and emergency services staff for identification and referral after possible adverse events, the creation of multidisciplinary teams for effective communication and management, straightforward patient intake processes encompassing financial eligibility review and provision of patient education materials, and close patient monitoring throughout the treatment journey. In Phase 2, 5 participants from 2 centers were interviewed. In Phase 3, 14 participants across 6 treatment centers were interviewed. Two 90-minute virtual panel discussions took place. All participants agreed that cilta-cel can be safely and effectively administered in an outpatient setting. Key recommendations included the creation of educational resources for patients and caregivers, the development of standard operating procedures, dedicated outpatient infrastructure and establishment of interdisciplinary teams, outpatient monitoring for toxicity management, and monitoring of the reimbursement landscape.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study offers a comprehensive understanding of the feasibility of outpatient cilta-cel administration in participating CAR T centers and provides actionable recommendations while acknowledging existing challenges.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1405452","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:35:39Z","timestamp":1718134539000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma"],"prefix":"10.3389","volume":"15","author":[{"given":"Doris K.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lodowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Okorozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Perciavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2515135520927164","DOI":"10.1177\/2515135520927164","article-title":"CAR T-cell immunotherapy of B-cell Malignancy: the story so far","volume":"8","author":"Halim","year":"2020","journal-title":"Ther Adv Vaccines Immunother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.21037\/atm","article-title":"CAR T-cell therapy in mature lymphoid Malignancies: clinical opportunities and challenges","volume":"9","author":"Narkhede","year":"2021","journal-title":"Ann Transl Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050378","article-title":"Management and prevention of cellular-therapy-related toxicity: Early and late complications","volume":"30","author":"Mucha","year":"2023","journal-title":"Curr Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B9","volume-title":"(axicabtagene ciloleucel) [package insert]","year":"2023"},{"key":"B10","volume-title":"(idecabtagene vicleucel) [package insert]","author":"Princeton","year":"2021"},{"key":"B11","unstructured":"Carvykti - Adverse Event - Cytokine Release Syndrome (CRS)2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2147\/OTT.S305429","article-title":"Evaluating the therapeutic potential of idecabtagene vicleucel in the treatment of multiple myeloma: Evidence to date","volume":"15","author":"Mann","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2019-124750","article-title":"Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S388","DOI":"10.1016\/j.jtct.2023.12.543","article-title":"Evaluation of outpatient administration of ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma: Single center experience","volume":"30","author":"Waqar","year":"2024","journal-title":"Transplant Cell Therapy Off Publ Am Soc Transplant Cell Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1016\/j.jtct.2023.12.274","article-title":"Outpatient administration of commercial antiCD19 and antibcma chimeric antigen receptor-modified T-cell (CAR-T) therapies using a strategy of no remote monitoring and early cytokine release syndrome (CRS) intervention","volume":"30","author":"Furqan","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.242","article-title":"Safety and feasibility of outpatient administration of ciltacabtagene autoleucel (Cilta-cel)","volume":"30","author":"Ly","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1200\/JCO.2022.40.16_suppl.8020","article-title":"Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1\u20133 prior lines of therapy (LOT): CARTITUDE-2, cohort A","volume":"40","author":"Einsele","year":"2022","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8029","DOI":"10.1200\/JCO.2022.40.16_suppl.8029","article-title":"Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B","volume":"40","author":"van de Donk","year":"2022","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: Barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.jtct.2023.12.530","article-title":"Cost per responder analysis of patients with lenalidomide-Refractory multiple myeloma who\u00a0received cilta-Cel from the cartitude-4 trial","author":"Hansen","year":"2024","journal-title":"Transplant Cell Ther Meetings;"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4211-4","article-title":"Quality of life in cancer patients\u2014a comparison of inpatient, outpatient, and rehabilitation settings","volume":"26","author":"Hinz","year":"2018","journal-title":"Supportive Care Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2019-131761","article-title":"Home or away from home: A multi-institution study comparing medical outcomes, patient perspectives, and health-related quality of life for outpatient versus inpatient management after chemotherapy for pediatric acute myeloid leukemia","volume":"134","author":"Getz","year":"2019","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702534","article-title":"A comparison of inpatient and outpatient ASCT","volume":"26","author":"Summers","year":"2000","journal-title":"Bone Marrow Transplantation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.3390\/cancers15245746","article-title":"The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: A systematic literature review","volume":"15","author":"Hansen","year":"2023","journal-title":"Cancers"},{"key":"B25","unstructured":"Carvykti Treatment Center Locator2023"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.02.018","article-title":"Building a CAR garage: Preparing for the delivery of commercial CAR T cell products at memorial sloan kettering cancer center","volume":"24","author":"Perica","year":"2018","journal-title":"Biol Blood Marrow Transplantation"},{"key":"B27","article-title":"What's keeping CAR T-cell therapies from the outpatient setting","volume":"20","author":"Lewis","year":"2019","journal-title":"OncLive"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1188\/19.CJON.S1.20-26","article-title":"Building a program: implications for infrastructure, nursing education, and training for CAR T-cell therapy","volume":"23","author":"Taylor","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"B29","article-title":"CAR T cells may be safely administered in outpatient setting for patients with B-cell lymphomas targeted oncology","author":"Ternyila","year":"2020","journal-title":"Targeted Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.01.014","article-title":"Chimeric antigen receptor T cell therapy: A comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration","volume":"27","author":"Alexander","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.1200\/JCO.2021.39.15_suppl.7554","article-title":"Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma","volume":"39","author":"Bansal","year":"2021","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1182\/blood-2021-153457","article-title":"Successful development of an outpatient chimeric antigen receptor (CAR) T cell therapy program","volume":"138","author":"Borogovac","year":"2021","journal-title":"Blood"},{"key":"B33","unstructured":"Addressing Logistical Challenges of CAR T Therapy Administration in Inpatient, Outpatient Settings Pharmacy Times\n            CraigF\n            LinA\n            HippensteeleA\n          2021"},{"key":"B34","doi-asserted-by":"publisher","first-page":"151178","DOI":"10.1016\/j.soncn.2021.151178","article-title":"Tisagenlecleucel therapy: Nursing considerations for the outpatient setting","volume":"37","author":"Cunningham","year":"2021","journal-title":"Semin Oncol Nursing"},{"key":"B35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jha2.333","article-title":"Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration","volume":"3","author":"Gatwood","year":"2022","journal-title":"EJHaem"},{"key":"B36","unstructured":"Proposals to cap Medicare Part B payments will limit outpatient access to CAR-T STAT\n            MaziarzR\n            SnyderS\n          2021"},{"key":"B37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1182\/blood-2021-149103","article-title":"Pilot implementation of remote patient monitoring program for outpatient management of CAR-T cell therapy","volume":"138","author":"Paludo","year":"2021","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"B39","unstructured":"Hospitals Still Grappling With $1 M+ Price Tag for CAR-T Rx Pharmacy Practice News\n            ShawG\n          2021"},{"key":"B40","article-title":"Can CAR T-cell rx be moved outside hospital","volume-title":"Pharmacy Practice News","author":"Shaw","year":"2022"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.25270\/jcp.2018.10.00039","article-title":"Evolving the delivery of CAR T-cell therapies to the outpatient setting","volume":"4","author":"Smith","year":"2018","journal-title":"J Clin Pathways"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.11.008","article-title":"Chimeric Antigen Receptor T-Cell therapy in the outpatient setting: An expert panel opinion from the American society for transplantation and cellular therapy","volume":"30","author":"Oluwole","year":"2024","journal-title":"Transplant Cell Therapy Off Publ Am Soc Transplant Cell Ther"},{"key":"B43","volume-title":"(ciltacabtagene autoleucel) [package insert]","year":"2023"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.014","article-title":"Optimizing the CAR T-cell therapy experience in multiple myeloma: Clinical pearls from an expert roundtable","volume":"24","author":"Ailawadhi","year":"2024","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.196","article-title":"Building the future of CAR-T therapy: Empowering clinicians through an outpatient infrastructure development workshop","volume":"30","author":"DeLuca","year":"2024","journal-title":"Transplant Cell Therapy Off Publ Am Soc Transplant Cell Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159595","article-title":"Results from outreach: A phase 2 study of lisocabtagene maraleucel (Liso-cel) administered as outpatient (Outpt) or inpatient (Inpt) treatment in the community\/nonuniversity setting in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"140","author":"Linhares","year":"2022","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2021-148792","article-title":"Outreach: results from a phase 2 study of lisocabtagene maraleucel (liso-cel) administered as inpatient (Inpt) or outpatient (Outpt) treatment in the nonuniversity setting in patients (Pts) with R\/R large B-Cell lymphoma (LBCL)","volume":"138","author":"Godwin","year":"2021","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1910686","article-title":"Postinfusion monitoring costs by site of care for patients with relapsed\/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials","volume":"62","author":"Palomba","year":"2021","journal-title":"Leukemia Lymphoma"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19090","article-title":"Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages","volume":"203","author":"Ly","year":"2023","journal-title":"Br J Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1405452\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:35:46Z","timestamp":1718134546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1405452\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2024.1405452"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1405452","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"article-number":"1405452"}}